Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) insider Catriona Yale sold 5,745 shares of the company’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $49.99, for a total value of $287,192.55. Following the transaction, the insider now directly owns 46,627 shares of the company’s stock, valued at approximately $2,330,883.73. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Catriona Yale also recently made the following trade(s):
- On Friday, June 23rd, Catriona Yale sold 11,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $50.76, for a total value of $558,360.00.
- On Wednesday, June 21st, Catriona Yale sold 11,349 shares of Akero Therapeutics stock. The stock was sold at an average price of $52.26, for a total value of $593,098.74.
Akero Therapeutics Stock Down 0.2 %
AKRO opened at $49.63 on Friday. Akero Therapeutics, Inc. has a 1-year low of $10.48 and a 1-year high of $58.38. The stock’s fifty day simple moving average is $45.46 and its 200 day simple moving average is $44.89. The company has a current ratio of 29.77, a quick ratio of 29.78 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.76 billion, a PE ratio of -19.39 and a beta of -0.93.
Wall Street Analysts Forecast Growth
AKRO has been the topic of a number of analyst reports. UBS Group initiated coverage on Akero Therapeutics in a research note on Monday. They set a “buy” rating and a $83.00 price objective on the stock. HC Wainwright upped their price objective on Akero Therapeutics from $62.00 to $64.00 in a research note on Wednesday, June 7th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $57.50.
Institutional Investors Weigh In On Akero Therapeutics
A number of large investors have recently added to or reduced their stakes in the business. Avidity Partners Management LP raised its stake in Akero Therapeutics by 22.5% in the 4th quarter. Avidity Partners Management LP now owns 3,825,000 shares of the company’s stock valued at $209,610,000 after acquiring an additional 703,000 shares during the period. BlackRock Inc. increased its position in Akero Therapeutics by 19.3% during the 2nd quarter. BlackRock Inc. now owns 3,321,153 shares of the company’s stock worth $155,065,000 after buying an additional 537,776 shares during the period. Alkeon Capital Management LLC increased its position in Akero Therapeutics by 2.6% during the 4th quarter. Alkeon Capital Management LLC now owns 3,243,915 shares of the company’s stock worth $177,767,000 after buying an additional 81,656 shares during the period. Price T Rowe Associates Inc. MD increased its position in Akero Therapeutics by 9.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,623,680 shares of the company’s stock worth $100,383,000 after buying an additional 222,643 shares during the period. Finally, State Street Corp increased its position in Akero Therapeutics by 0.4% during the 2nd quarter. State Street Corp now owns 2,240,231 shares of the company’s stock worth $104,596,000 after buying an additional 9,424 shares during the period.
About Akero Therapeutics
Akero Therapeutics, Inc, a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
- Five stocks we like better than Akero Therapeutics
- How to Invest in Solar Energy
- 3 Takeaways from the August Inflation Report
- How to Invest in Cannabis, Step by Step
- On Fire: 5 Best Artificial Intelligence Penny Stocks
- How to Calculate Return on Investment (ROI)
- 6 Cybersecurity Stocks: Which is the Best to Buy?
Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.